Unknown

Dataset Information

0

Differential response of regulatory and conventional CD4? lymphocytes to CD3 engagement: clues to a possible mechanism of anti-CD3 action?


ABSTRACT: Several clinical trials have shown anti-CD3 treatment to be a promising therapy for autoimmune diabetes, but its mechanism of action remains unclear. Foxp3(+) regulatory T cells (Tregs) are likely to be involved, but through unknown mechanistic pathways. We profiled the transcriptional consequences in CD4(+) Tregs and conventional T cells (Tconvs) in the first hours and days after anti-CD3 treatment of NOD mice. Anti-CD3 treatment led to a transient transcriptional response, terminating faster than most Ag-induced responses. Most transcripts were similarly induced in Tregs and Tconvs, but several were differential, in particular, those encoding the IL-7R and transcription factors Id2/3 and Gfi1, upregulated in Tregs but repressed in Tconvs. Because IL-7R was a plausible candidate for driving the homeostatic response of Tregs to anti-CD3, we tested its relevance by supplementation of anti-CD3 treatment with IL-7/anti-IL-7 complexes. Although ineffective alone, IL-7 significantly improved the rate of remission induced by anti-CD3. Four anti-human CD3 mAbs exhibited the same differential effect on IL-7R expression in human as in mouse cells, suggesting that the mechanism also underlies therapeutic effect in human cells, and perhaps a rationale for testing a combination of anti-CD3 and IL-7 for the treatment of recent-onset human type 1 diabetes. Thus, systems-level analysis of the response to anti-CD3 in the early phase of the treatment demonstrates different responses in Tregs and Tconvs, and provides new leads to a mechanistic understanding of its mechanism of action in reverting recent-onset diabetes.

SUBMITTER: Li L 

PROVIDER: S-EPMC3932531 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Differential response of regulatory and conventional CD4⁺ lymphocytes to CD3 engagement: clues to a possible mechanism of anti-CD3 action?

Li Li L   Nishio Junko J   van Maurik André A   Mathis Diane D   Benoist Christophe C  

Journal of immunology (Baltimore, Md. : 1950) 20130828 7


Several clinical trials have shown anti-CD3 treatment to be a promising therapy for autoimmune diabetes, but its mechanism of action remains unclear. Foxp3(+) regulatory T cells (Tregs) are likely to be involved, but through unknown mechanistic pathways. We profiled the transcriptional consequences in CD4(+) Tregs and conventional T cells (Tconvs) in the first hours and days after anti-CD3 treatment of NOD mice. Anti-CD3 treatment led to a transient transcriptional response, terminating faster t  ...[more]

Similar Datasets

| S-EPMC5813697 | biostudies-literature
| S-EPMC6599059 | biostudies-literature
| S-EPMC2755768 | biostudies-literature
| S-EPMC3369608 | biostudies-literature
| S-EPMC3141315 | biostudies-literature
2013-07-01 | E-GEOD-48210 | biostudies-arrayexpress
| S-EPMC6219428 | biostudies-literature
| S-EPMC9282886 | biostudies-literature
| S-EPMC9355928 | biostudies-literature
2013-07-01 | GSE48210 | GEO